Showing 4081-4090 of 4773 results for "".
- Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointmenthttps://practicaldermatology.com/news/aqua-pharmaceuticals-acquires-us-rights-to-veltin-gel-and-altabax-ointment/2458795/Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and
- New Therapeutic Skin Care Line From Galdermahttps://practicaldermatology.com/news/new-therapeutic-skin-care-line-from-galderma/2458852/Galderma Laboratories, LP, makers of Cetaphil, unveiled a new therapeutic skincare line precisely engineered for challenged skin—Excipial. It will be available over the counter and without a prescription. Excipial products are formulated with ingredients to heal, relieve, protect, and repai
- DermTube Offers Video Coverage of NewDerm Live Meetinghttps://practicaldermatology.com/news/dermtube-offers-video-coverage-of-newderm-live-meeting/2458865/NewDerm LIVE, a new meeting for dermatologists just starting out in practice—as well as those not so new to practice—has brought a unique meeting format into the dermatology space. The meeting, supported by the publishers of Practical Dermatology® magazine and NewDerm
- Galderma Finalizes Expansion in Aesthetic and Corrective Dermatologyhttps://practicaldermatology.com/news/20140710-galderma_finalizes_expansion_in_aesthetic_and_corrective_dermatology/2459175/Galderma S.A. has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra, and Dysport from Valeant Pharmaceuticals International, Inc. “We at Galderma are delighted to bring Restylane, Perlane, Emervel, and Dysport home in the U.S. and
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
- Jeffrey T. S. Hsu, MD, FAADhttps://practicaldermatology.com/profiles/jeffrey-t-s-hsu-md-faad/74v190/
- Jeffrey Rapaport, MDhttps://practicaldermatology.com/profiles/jeffrey-rapaport-md/jVVKp6/